Ultimovacs

Ultimovacs Overview

Founded 2011
Founded
Status Public
Employees 17
Employees
Stock Symbol ULTIMO
Stock Symbol
Investments 1
Share Price $4.85 (As of Tuesday Closing)

Ultimovacs General Information

Description

Ultimovacs ASA is a Norway based pharmaceutical company involved in developing novel immunotherapies against cancer. Its product candidate is UV1, a peptide-based vaccine inducing T cell responses against the universal cancer antigen telomerase. The company and its proprietary technology is based on preclinical and clinical research on immunotherapies conducted at the Oslo University Hospital.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly PE-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Stock Exchange
OSL
Primary Office
  • Ullernchausséen 64
  • 0379 Oslo
  • Norway
+47 413 00 000
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Ultimovacs Stock Performance

(As of Tuesday closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$4.85 $4.54 $2.33 - $8.25 $135M 27.9M 38.3K -$0.32

Ultimovacs Financials Summary

In Thousands,
USD
TTM 31-Mar-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018 FY 2017 31-Dec-2017
EV 43,875 78,800
Revenue 0 0 0 0
EBITDA (8,937) (7,343) (6,869) (3,974)
Net Income (8,499) (6,948) (6,788) (3,970)
Total Assets 42,923 54,203 21,792 21,777
Total Debt 370 411 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Ultimovacs Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Ultimovacs‘s full profile, request access.

Request a free trial

Ultimovacs Executive Team (7)

Name Title Board Seat Contact Info
Øyvind Kongstun Arnesen MD Chief Executive Officer
Hans Eid Chief Financial Officer
Audun Tornes Chief Operating Officer
Sara Mangsbo Ph.D Chief Development Officer
Gustav Gaudernack Chief Scientific Officer

1 Former Executive

Ultimovacs Board Members (9)

To view Ultimovacs‘s full board member team, request access »
Name Representing Role Since
00000 00000000 000000 Self Board Member 000 0000
00ø00 00000000 Gjelsten Holding Board Member 000 0000
000000 000ü00000 Gjelsten Holding Board Member 000 0000
00000 000000000 00 Self Board Member 000 0000
00000 000000000 Ultimovacs Chairman 000 0000

Ultimovacs Investments (1)

To view Ultimovacs‘s complete investment and acquisition history, request access »
Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000000 03-Sep-2018 0000000000 00.000 Drug Discovery 0000 0000000 00.0

Ready to get started?

Request a free trial

Ultimovacs Subsidiaries (1)

Company Name Industry Location Founded
00000000 Drug Discovery Uppsala, Sweden 0000